198 related articles for article (PubMed ID: 18591558)
1. Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor.
Daud AI; Mirza N; Lenox B; Andrews S; Urbas P; Gao GX; Lee JH; Sondak VK; Riker AI; Deconti RC; Gabrilovich D
J Clin Oncol; 2008 Jul; 26(19):3235-41. PubMed ID: 18591558
[TBL] [Abstract][Full Text] [Related]
2. Treatment with tumor necrosis factor-alpha and granulocyte-macrophage colony-stimulating factor increases epidermal Langerhans' cell numbers in cancer patients.
Janik JE; Miller LL; Kopp WC; Taub DD; Dawson H; Stevens D; Kostboth P; Curti BD; Conlon KC; Dunn BK; Donegan SE; Ullrich R; Alvord WG; Gause BL; Longo DL
Clin Immunol; 1999 Dec; 93(3):209-21. PubMed ID: 10600331
[TBL] [Abstract][Full Text] [Related]
3. Recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF, sargramostim) administered for 3 years as adjuvant therapy of stages II(T4), III, and IV melanoma.
Spitler LE; Weber RW; Allen RE; Meyer J; Cruickshank S; Garbe E; Lin HY; Soong SJ
J Immunother; 2009; 32(6):632-7. PubMed ID: 19483646
[TBL] [Abstract][Full Text] [Related]
4. Intradermal injection of granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with metastatic melanoma recruits dendritic cells.
Nasi ML; Lieberman P; Busam KJ; Prieto V; Panageas KS; Lewis JJ; Houghton AN; Chapman PB
Cytokines Cell Mol Ther; 1999 Sep; 5(3):139-44. PubMed ID: 10641571
[TBL] [Abstract][Full Text] [Related]
5. Overlapping human leukocyte antigen class I/II binding peptide vaccine for the treatment of patients with stage IV melanoma: evidence of systemic immune dysfunction.
; Celis E
Cancer; 2007 Jul; 110(1):203-14. PubMed ID: 17541944
[TBL] [Abstract][Full Text] [Related]
6. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma.
Soiffer R; Hodi FS; Haluska F; Jung K; Gillessen S; Singer S; Tanabe K; Duda R; Mentzer S; Jaklitsch M; Bueno R; Clift S; Hardy S; Neuberg D; Mulligan R; Webb I; Mihm M; Dranoff G
J Clin Oncol; 2003 Sep; 21(17):3343-50. PubMed ID: 12947071
[TBL] [Abstract][Full Text] [Related]
7. Granulocyte colony-stimulating factor mobilizes more dendritic cell subsets than granulocyte-macrophage colony-stimulating factor with no polarization of dendritic cell subsets in normal donors.
Shaughnessy PJ; Bachier C; Lemaistre CF; Akay C; Pollock BH; Gazitt Y
Stem Cells; 2006 Jul; 24(7):1789-97. PubMed ID: 16822885
[TBL] [Abstract][Full Text] [Related]
8. Tumor-specific CD8+ T cell reactivity in the sentinel lymph node of GM-CSF-treated stage I melanoma patients is associated with high myeloid dendritic cell content.
Vuylsteke RJ; Molenkamp BG; van Leeuwen PA; Meijer S; Wijnands PG; Haanen JB; Scheper RJ; de Gruijl TD
Clin Cancer Res; 2006 May; 12(9):2826-33. PubMed ID: 16675577
[TBL] [Abstract][Full Text] [Related]
9. Intracerebral granulocyte-macrophage colony-stimulating factor induces functionally competent dendritic cells in the mouse brain.
Mausberg AK; Jander S; Reichmann G
Glia; 2009 Sep; 57(12):1341-50. PubMed ID: 19229994
[TBL] [Abstract][Full Text] [Related]
10. A phase 1 study of granulocyte macrophage colony-stimulating factor (sargramostim) and escalating doses of thalidomide in patients with high-risk malignant melanoma.
Lutzky J; Weber R; Nunez Y; Gillett M; Spitler L
J Immunother; 2009 Jan; 32(1):79-85. PubMed ID: 19307996
[TBL] [Abstract][Full Text] [Related]
11. Granulocyte-macrophage colony-stimulating factor alone or with dacarbazine in metastatic melanoma: a randomized phase II trial.
Ravaud A; Delaunay M; Chevreau C; Coulon V; Debled M; Bret-Dibat C; Courbon F; Gualde N; Nguyen Bui B
Br J Cancer; 2001 Nov; 85(10):1467-71. PubMed ID: 11720430
[TBL] [Abstract][Full Text] [Related]
12. Benefits of gene transduction of granulocyte macrophage colony-stimulating factor in cancer vaccine using genetically modified dendritic cells.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Nakamori M; Ueda K; Naka T; Katsuda M; Miyazawa M; Yamaue H
Int J Oncol; 2007 Oct; 31(4):931-9. PubMed ID: 17786327
[TBL] [Abstract][Full Text] [Related]
13. Ovarian carcinoma cells influence differentiation of Lin-CD45RA- dendritic cell precursors into two mature subtypes in vitro.
Chen LL; Ye F; Yu Y; Chen HZ; Zhang WW; Lü WG; Xie X
Gynecol Oncol; 2009 Jan; 112(1):199-204. PubMed ID: 19022493
[TBL] [Abstract][Full Text] [Related]
14. Generation of blood-derived dendritic cells in dogs with oral malignant melanoma.
Catchpole B; Stell AJ; Dobson JM
J Comp Pathol; 2002; 126(2-3):238-41. PubMed ID: 11945016
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor.
Spitler LE; Grossbard ML; Ernstoff MS; Silver G; Jacobs M; Hayes FA; Soong SJ
J Clin Oncol; 2000 Apr; 18(8):1614-21. PubMed ID: 10764421
[TBL] [Abstract][Full Text] [Related]
16. Activation of dendritic-like cells and neural stem/progenitor cells in injured spinal cord by GM-CSF.
Hayashi K; Ohta S; Kawakami Y; Toda M
Neurosci Res; 2009 May; 64(1):96-103. PubMed ID: 19428687
[TBL] [Abstract][Full Text] [Related]
17. The impact of concurrent granulocyte macrophage-colony stimulating factor on radiation-induced mucositis in head and neck cancer patients: a double-blind placebo-controlled prospective phase III study by Radiation Therapy Oncology Group 9901.
Ryu JK; Swann S; LeVeque F; Scarantino CW; Johnson D; Chen A; Fortin A; Pollock J; Kim H; Ang KK
Int J Radiat Oncol Biol Phys; 2007 Mar; 67(3):643-50. PubMed ID: 17293228
[TBL] [Abstract][Full Text] [Related]
18. Role of tumor-derived proinflammatory cytokines GM-CSF, TNF-alpha, and IL-12 in the migration and differentiation of antigen-presenting cells in cervical carcinoma.
Zijlmans HJ; Fleuren GJ; Baelde HJ; Eilers PH; Kenter GG; Gorter A
Cancer; 2007 Feb; 109(3):556-65. PubMed ID: 17177206
[TBL] [Abstract][Full Text] [Related]
19. In vitro inducing effect of dendritic cells cotransfected with survivin and granulocyte-macrophage colony-stimulating factor on cytotoxic T cell to kill leukemic cells.
Zhu XP; Chen ZZ; Li CT; Lin X; Zhuang JL; Hu JD; Yang T; Xu ZS
Chin Med J (Engl); 2008 Nov; 121(21):2180-4. PubMed ID: 19080181
[TBL] [Abstract][Full Text] [Related]
20. Granulocyte-macrophage-colony-stimulating factor and other cytokines: as adjuncts to cancer immunotherapy, stem cell transplantation, and vaccines.
Arellano M; K Waller E
Curr Hematol Rep; 2004 Nov; 3(6):424-31. PubMed ID: 15496276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
